SenzaGen
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Building 401 Medicon Village, Lund, Skan...Phone Number
+46 462756000Website
www.senzagen.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About SenzaGen
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SenzaGen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if SenzaGen had a recent Job posting/layoffs
Funding: Get notified immidiatlly once SenzaGen has new funding data
Earning: See what the market has to say on SenzaGen recently announced quarterly report
Product Launch: Get notified when SenzaGen launches new products
Check if SenzaGen has recently received funding, and reach out quickly before it becomes old news!
SenzaGen, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if SenzaGen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at SenzaGen
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
SenzaGen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SenzaGen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SenzaGen.
SenzaGen Tech Stack
A closer look at the technologies used by SenzaGen
See more technologies
Most Recent Scoops
Earnings
SenzaGen has announced that its Victroscreen division reported Q1 sales at Q4 levels, but with significantly higher order intake. The company enters Q2 with a much higher order book, showing signs of recovery after leadership changes made in late 2024.
Earnings, Sales, Finance
Earnings
reported that its current serviceable market is $0.5 billion, within a total market for effect and toxicity testing estimated at $13 billion. The market is projected to grow 6-9.5% annually from 2024-2025.
Earnings, Forecasting, Finance
Project
SenzaGen is focusing on driving sales through industry influence and scientific innovation, building out its commercial organization, releasing its newly recruited VitroScreen commercial team to market, continuing R&D to expand its test portfolio and drive regulatory approvals, and evaluating potential acquisitions to contribute to its growth journey.
Research & Development, Sales, Corporate Strategy
Earnings
reported current quarter revenue of 13.7M SEK leading to -1.3M SEK EBITDA, with breakeven expected around 15M SEK revenue, a level that has been reached historically.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Earnings, Sales, Customer Retention & Development, Finance
SenzaGen News & Media
SenzaGen secures 1.3 MSEK order for GARD®skin Dose-Response from leading global ...
SenzaGen has received an importanttesting assignment from a globally leading actor in the chemical industry. The order is valued at approximately 1.3 million SEK and includes testing using SenzaGen's innovative and non-animal test method for skin sensitization, the unique GARD®skin Dose-Response te…SenzaGen Secures SEK 1.7 Million Order from a New Global Biotech Industry Leader
SenzaGen has been selected to test substances for yet another new global customer within the biotech industry. The assignment is valued at SEK 1.7 million and includes non-animal tests for skin...BioStock Studio: SenzaGen is aiming to increase market activity in 2021
Lund-based biotech company SenzaGen has developed animal-free test methods to assess allergenicity of substances, directed towards four industry segments: pharmaceuticals, medical devices, cosmetics, and the chemicals industry. Recently, the company published its year-end report for 2020, which was a period of transition with focus on the market, sales and regulatory processes. SenzaGen’s CEO Axel Sjöblad visited BioStock’s studio and talked about the report, ongoing projects and what we can expIf You Had Bought SenzaGen (STO:SENZA) Stock A Year Ago, You'd Be Sitting On A 53% Loss, Today
Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of SenzaGen AB...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SenzaGen
Sign Up For FreeTo access detailed company insights
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test... Read More
